The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures
Open accessAbstract
Malignant ascites indicates the presence of malignant cells in the peritoneal cavity and is a grave prognostic sign. While survival in this patient population is poor, averaging about 20 wk from time of diagnosis, quality of life can be improved through palliative procedures. Selecting the appropriate treatment modality remains a careful process, which should take into account potential risks and benefits and the life expectancy of the patient. Traditional therapies, including paracentesis, peritoneovenous shunt placement and diuretics, are successful and effective in varying degrees. After careful review of the patient's primary tumor origin, tumor biology, tumor stage, patient performance status and comorbidities, surgical debulking and intraperitoneal chemotherapy should be considered if the benefit of therapy outweighs the risk of operation because survival curves can be extended and palliation of symptomatic malignant ascites can be achieved in select patients. In patients with peritoneal carcinomatosis who do not qualify for surgical cytoreduction but suffer from the effects of malignant ascites, intraperitoneal chemotherapy can be safely and effectively administered via laparoscopic techniques. Short operative times, short hospital stays, low complication rates and ultimately symptomatic relief are the advantages of laparoscopically administering heated intraperitoneal chemotherapy, making it not only a valuable treatment modality but also the most successful treatment modality for achieving palliative cure of malignant ascites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.012 · Cited by 1,184
Vascular permeability, vascular hyperpermeability and angiogenesis
Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M., & Dvorak, H. F. (2008) · Angiogenesis · doi:10.1007/s10456-008-9099-z · Cited by 628
Runyon, B. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402033300508 · Cited by 400
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 385
Ascitic fluid analysis in malignancy-related ascites
Runyon, B. A., Hoefs, J. C., & Morgan, T. R. (1988) · Hepatology · doi:10.1002/hep.1840080521 · Cited by 361
Malignant ascites: Systematic review and guideline for treatment
Becker, G., Galandi, D., & Blum, H. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.018 · Cited by 349
Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts.
Tarin, D., Price, J. E., Kettlewell, M. G. W., Souter, R. G., Ac, V., & Crossley, B. (1984) · PubMed · Cited by 303
Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites
Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0373-0 · Cited by 254
Malignant ascites: past, present, and future
Adam, R. A., & Adam, Y. G. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.035 · Cited by 209
Malignant Ascites: Clinical and Experimental Observations
GARRISON, R. N., KAELIN, L. D., HEUSER, L. S., & GALLOWAY, R. H. (1986) · Annals of Surgery · doi:10.1097/00000658-198606000-00009 · Cited by 208
The Current and Future Management of Malignant Ascites
Smith, E. M., & Jayson, G. C. (2003) · Clinical Oncology · doi:10.1053/clon.2002.0135 · Cited by 167
Clinical and Experimental Observations
Koff, S. A. (1990) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00886-7 · Cited by 167
Jc, H. (1983) · PubMed · Cited by 165
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis
McQuellon, R. P., Loggie, B. W., Fleming, R. A., Russell, G. B., Lehman, A. B., & Rambo, T. D. (2001) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.2000.1033 · Cited by 163
The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.
Feldman, G. B., KNAPP, R. C., Order, S. E., & Hellmän, S. (1972) · PubMed · Cited by 133
Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.
Nagy, J. A., Herzberg, K. T., Dvorak, J. M., & Dvorak, H. F. (1993) · PubMed · Cited by 93
PATHOGENESIS OF ASCITES IN PERITONEAL CARCINOMATOSIS1
Holm-Nielsen, P. (1953) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1953.tb04805.x · Cited by 68
Malignant ascites: demographics, therapeutic efficacy and predictors of survival.
Mackey, J. R., & Venner, P. M. (1996) · PubMed · Cited by 67
Telomerase assay for differentiating between malignancy-related and nonmalignant ascites.
Tangkijvanich, P., Tresukosol, D., Sampatanukul, P., Sakdikul, S., Voravud, N., Mahachai, V., & Mutirangura, A. (1999) · PubMed · Cited by 33
Ströhlein, M. A., & Heiss, M. M. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21338 · Cited by 8
Cited by
Immunological Functions of the Omentum
Meza-Perez, S., & Randall, T. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.002 · Cited by 326
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.112 · Cited by 98
Marth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R., Kurzeder, C., Colombo, N., Vuylsteke, P., Lorusso, D., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.004 · Cited by 79
“particularly susceptible to treatment with anti-angiogenic agents [38,39].”
BackgroundNanoformulations of Albendazole As Effective Anticancer and Antiparasite Agents
Movahedi, F., Li, L., Gu, W., & Xu, Z. P. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0102 · Cited by 34
Metadata
- Authors
- Sangisetty, S. L.
- Venue
- World Journal of Gastrointestinal Surgery
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2012
- Volume
- 4
- Issue
- 4
- Pages
- 87
- ISSN
- 1948-9366 (ISSN-L)
- OpenAlex
- W2067651633
- Cited by
- 288
- References
- 22
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.